TNF and tuberculosis: Although TNF-α inhibitors signal a new era in the treatment of inflammatory bowel disease (IBD), contributing greatly to the improvement in disease prognosis [4,5], the use of these agents is associated with a 2–8-fold increased risk of active TB [1].